Galderma Announces Positive Phase 2 Results for its Proprietary Liquid Formulation of an Investigational Botulinum Toxin and Approval of New State-of-the-Art Manufacturing Facility
(WorldNews Health)

Results Demonstrate Safety and Long-Term Efficacy of QM1114 in 350 patients for the Treatment of Glabellar Lines Galderma Received Manufacturing License for its New Facilities at their Center of Excellence in Uppsala, Sweden Galderma Poised to Advance to Phase 3 Testing Lausanne, Switzerland - October 9, 2019 - Galderma, a global leader in skin health focused on developing innovative aesthetic solutions, recently announced the Phase 2 clinical trial results for its novel ready-to-use investigational botulinum toxin, QM1114. The multicenter, randomized, double-blind, placebo-controlled study successfully demonstrated the safety and efficacy of Galderma´s liquid formulation of botulinum...